An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

NCT00619866 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 155

Last updated 2018-09-07

Study results available
· View outcomes & findings →

Summary

This study is designed to see how elagolix works compared to placebo in women with endometriosis and to see the effect, if any, on bone mineral density.

Conditions

  • Endometriosis, Pain

Interventions

DRUG

Elagolix

Elagolix tablets administered orally

DRUG

placebo

Placebo tablet administered orally

Sponsors & Collaborators

Principal Investigators

  • AbbVie Inc. · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
49 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-02-19
Primary Completion
2009-04-20
Completion
2009-08-28
FDA Drug
Yes

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00619866 on ClinicalTrials.gov